Sanofi (SNY,SAN.PA) reported that its first quarter net income from continuing operations declined to 1.59 billion euros from 1.72 billion euros, prior year. Basic earnings per share from continuing operations was 1.32 euros compared to 1.39 euros. Business net income was 2.26 billion euros compared to 2.21 billion euros. Business earnings per share increased to 1.88 euros from 1.79 euros.
First quarter net sales were 10.51 billion euros compared to 9.89 billion euros, prior year. At actual exchange rates, sales increased by 6.2%. Dupixent sales increased by 30.8% to 4.2 billion euros.
Olivier Charmeil, interim CEO, said: "We had a strong start to 2026 with double-digit sales and business EPS growth. Sales increased by 13.6%, supported by Pharma launches and recent acquisitions."
Sanofi reiterated guidance for 2026. The company continues to expect sales to grow by a high single-digit percentage and business EPS to grow slightly faster than sales, at constant exchange rates, delivering profitable growth.
At last close, shares of Sanofi were trading at 80.78 euros, down 0.30%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.